Nevro Corp announced the full market launch of its HFX iQ spinal cord stimulation system for the treatment of chronic pain.
Nevro Corp, a global medical device company that creates solutions for treating chronic pain, announced that it has now initiated the US full market launch of its HFX iQ spinal cord stimulation (SCS) system, following the completion of a successful limited market release.
“This is an exciting time in spinal cord stimulation – better waveforms, more conditions we can treat, and a massive treasure trove of patient data,” said Usman Latif, MD, MBA, a Harvard-trained interventional pain specialist who practices at the University of Kansas Medical Center. “The way forward in this field is precision medicine powered by big data and artificial intelligence. HFX iQ is the future of medicine, where expanded data holds the promise of new capabilities and improved care.”
HFX iQ starts patients on the program most likely to provide pain relief, based on the HFX Algorithm, built from over 20 million data points and 80,000 implanted patients.
HFX iQ combines clinical inputs, such as pain relief and pain score, along with quality of life inputs, such as pain medication and activity level changes, to provide an individualized program setting for each patient.
According to Nevro Corp, it offers both low frequency and the company’s proprietary high-frequency 10 kHz Therapy, which represents the widest range of frequencies of any SCS system on the market. The Senza high-frequency 10 kHz Therapy has been validated in clinical and real-world outcomes. It offers AI-driven iQ modes for treating painful diabetic neuropathy and chronic back and leg pain, including non-surgical back pain.
“We are continuing to lead the way with the first big data-backed, AI-powered SCS system that gets smarter over time, learning from patient responses to deliver personalized relief to patients,” said D Keith Grossman, chairman, chief executive officer and president of Nevro. “With over 10 years of innovation and now over 100,000 patients served, Nevro brings the next big advancement to SCS therapy with HFX iQ, a system that will apply the big data we have collected over the last decade to help patients find pain relief faster and maintain that relief over time.”
The Senza HFX iQ system comprises the HFX iQ Implantable Pulse Generator (IPG), HFX Trial Stimulator, and HFX App. With a new Bluetooth-enabled IPG that is upgradeable and connects directly to the HFX App, each patient can input assessments into their smartphone and receive programming adjustments in real-time.
In addition to US approval for Senza HFX iQ, Nevro has submitted for approval in Europe and Australia.
Photo courtesy of Nevro Corp
